Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12614767.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). Interventional case report. A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. : The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.
Medical subject headings
- Antineoplastic Agents
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Piperazines
- Pyrimidines
- Retinal Neoplasms